Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.
Cortés-Sempere M, de Miguel MP, Pernía O, Rodriguez C, de Castro Carpeño J, Nistal M, Conde E, López-Ríos F, Belda-Iniesta C, Perona R, Ibanez de Caceres I. Cortés-Sempere M, et al. Among authors: nistal m. Oncogene. 2013 Mar 7;32(10):1274-83. doi: 10.1038/onc.2012.146. Epub 2012 Apr 30. Oncogene. 2013. PMID: 22543588
MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer.
Cortes-Sempere M, Chattopadhyay S, Rovira A, Rodriguez-Fanjul V, Belda-Iniesta C, Tapia M, Cejas P, Machado-Pinilla R, Manguan-García C, Sánchez-Pérez I, Nistal M, Moratilla C, de Castro-Carpeño J, Gonzalez-Barón M, Albanell J, Perona R. Cortes-Sempere M, et al. Among authors: nistal m. Cancer Lett. 2009 Dec 28;286(2):206-16. doi: 10.1016/j.canlet.2009.05.029. Epub 2009 Jun 23. Cancer Lett. 2009. PMID: 19553005
IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, Manguán-García C, Cejas P, López-Ríos F, Paz-Ares L, de CastroCarpeño J, Nistal M, Belda-Iniesta C, Perona R. Ibanez de Caceres I, et al. Among authors: nistal m. Oncogene. 2010 Mar 18;29(11):1681-90. doi: 10.1038/onc.2009.454. Epub 2009 Dec 21. Oncogene. 2010. PMID: 20023704
MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S, Machado-Pinilla R, Manguan-García C, Belda-Iniesta C, Moratilla C, Cejas P, Fresno-Vara JA, de Castro-Carpeño J, Casado E, Nistal M, Gonzalez-Barón M, Perona R. Chattopadhyay S, et al. Among authors: nistal m. Oncogene. 2006 Jun 1;25(23):3335-45. doi: 10.1038/sj.onc.1209364. Epub 2006 Feb 6. Oncogene. 2006. PMID: 16462770
New insights in beta-tubulin sequence analysis in non-small cell lung cancer.
de Castro J, Belda-Iniesta C, Cejas P, Casado E, Fresno Vara JA, Hardisson D, Sánchez JJ, Feliu J, Ordóñez A, Nistal M, González-Barón M. de Castro J, et al. Among authors: nistal m. Lung Cancer. 2003 Jul;41(1):41-8. doi: 10.1016/s0169-5002(03)00123-5. Lung Cancer. 2003. PMID: 12826311 Clinical Trial.
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study.
Ramírez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Tarón M, Ramírez de Molina V, Cejas P, Skrzypski M, Gallego-Ortega D, de Castro J, Casado E, García-Cabezas MA, Sánchez JJ, Nistal M, Rosell R, González-Barón M, Lacal JC. Ramírez de Molina A, et al. Among authors: nistal m. Lancet Oncol. 2007 Oct;8(10):889-97. doi: 10.1016/S1470-2045(07)70279-6. Lancet Oncol. 2007. PMID: 17851129
Inhibin bodies: a new marker for immature Sertoli cells.
Nistal M, Pastrián LG, González-Peramato P, De Miguel MP. Nistal M, et al. Histopathology. 2011 Jun;58(7):1019-27. doi: 10.1111/j.1365-2559.2011.03858.x. Histopathology. 2011. PMID: 21707703
333 results